These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 36003383)

  • 1. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
    Peng M
    Front Immunol; 2022; 13():970885. PubMed ID: 36003383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of fatty acid metabolism-related molecular subtype biomarkers and their correlation with immune checkpoints in cutaneous melanoma.
    Xu Y; Chen Y; Jiang W; Yin X; Chen D; Chi Y; Wang Y; Zhang J; Zhang Q; Han Y
    Front Immunol; 2022; 13():967277. PubMed ID: 36466837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer.
    Zheng H; Liu H; Li H; Dou W; Wang J; Zhang J; Liu T; Wu Y; Liu Y; Wang X
    Stem Cell Res Ther; 2022 Jun; 13(1):244. PubMed ID: 35681225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.
    Chen L; Lin J; Wen Y; Chen Y; Chen CB
    Front Oncol; 2023; 13():1291720. PubMed ID: 38023241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor stemness score to estimate epithelial-to-mesenchymal transition (EMT) and cancer stem cells (CSCs) characterization and to predict the prognosis and immunotherapy response in bladder urothelial carcinoma.
    Zhang Y; Zhang X; Huang X; Tang X; Zhang M; Li Z; Hu X; Zhang M; Wang X; Yan Y
    Stem Cell Res Ther; 2023 Feb; 14(1):15. PubMed ID: 36721217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell atlases link macrophages and CD8
    Liang Y; Tan Y; Guan B; Guo B; Xia M; Li J; Shi Y; Yu Z; Zhang Q; Liu D; Yang X; Hao J; Gong Y; Shakeel M; Zhou L; Ci W; Li X
    Theranostics; 2022; 12(18):7745-7759. PubMed ID: 36451860
    [No Abstract]   [Full Text] [Related]  

  • 7.
    Zhao X; Hu J; Li J; Gu L; Chen J; Othmane B; Gong G; Yuan J; Deng H
    Dis Markers; 2022; 2022():7147279. PubMed ID: 35909893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 9. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploring the Shared Gene Signatures and Molecular Mechanisms between Bladder Urothelial Carcinoma and Metabolic Syndrome.
    Li C; Wan Z; Deng Q; Li Z; Wang Y
    Arch Esp Urol; 2023 Oct; 76(8):605-621. PubMed ID: 37960960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor mutational burden related classifier is predictive of response to PD-L1 blockade in locally advanced and metastatic urothelial carcinoma.
    Wang Y; Chen L; Ju L; Xiao Y; Wang X
    Int Immunopharmacol; 2020 Oct; 87():106818. PubMed ID: 32738594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
    Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
    BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor immune dysfunction and exclusion subtypes in bladder cancer and pan-cancer: a novel molecular subtyping strategy and immunotherapeutic prediction model.
    Zheng K; Hai Y; Chen H; Zhang Y; Hu X; Ni K
    J Transl Med; 2024 Apr; 22(1):365. PubMed ID: 38632658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MLKL and other necroptosis-related genes promote the tumor immune cell infiltration, guiding for the administration of immunotherapy in bladder urothelial carcinoma.
    Zhong B; Wang Y; Liao Y; Liang J; Wang K; Zhou D; Zhao Y; Jiang N
    Apoptosis; 2023 Jun; 28(5-6):892-911. PubMed ID: 37000317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of prognostic oncogene filaggrin (
    Chen L; Huang X; Xiong L; Chen W; An L; Wang H; Hong Y; Wang H
    Transl Androl Urol; 2022 Oct; 11(10):1419-1432. PubMed ID: 36386263
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S
    BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The G protein-coupled receptor-related gene signatures for predicting prognosis and immunotherapy response in bladder urothelial carcinoma.
    Wan Z; Wang Y; Li C; Zheng D
    Open Life Sci; 2023; 18(1):20220682. PubMed ID: 37588995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and molecular characteristics of bladder urothelial carcinoma subtypes.
    Li Y; Yang K; Li K; Liu H; Zhao S; Jiao M; Fu X
    J Cell Biochem; 2019 Jun; 120(6):9956-9963. PubMed ID: 30548659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
    Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
    Front Immunol; 2022; 13():898493. PubMed ID: 35812369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD93 orchestrates the tumor microenvironment and predicts the molecular subtype and therapy response of bladder cancer.
    Zheng X; Xu H; Lin T; Tan P; Xiong Q; Yi X; Qiu S; Yang L; Shen B; Ai J; Wei Q
    Comput Biol Med; 2022 Aug; 147():105727. PubMed ID: 35785664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.